CXDX Connected Diagnostics, a medical technology solutions company based in Newcastle, Australia, is thrilled to announce that the NeuroCatch Platform® is now included in the Australian Register of Therapeutic Goods (ARTG number 439393). This landmark achievement introduces an objective, rapid, and cutting-edge neurological assessment tool to the Australian healthcare market.
Michael Dirienzo, Chief Executive of CXDX, expressed his excitement, "Bringing NeuroCatch to Australia is not just a milestone for CXDX but a significant advancement in healthcare, especially in brain health." Dirienzo further stated, "Our mission is to ensure that cutting-edge healthcare technology is accessible to all Australians. NeuroCatch's introduction is a leap towards achieving that goal, marking a new era in treating and caring for brain health conditions."
The NeuroCatch Platform® is a medical device that offers an objective evaluation of cognitive function, which is delivered in minutes at the point of care. The NeuroCatch Platform® can provide value at any time in the care continuum, from initial evaluation or post-injury through ongoing treatment, with immediate results to help guide clinical decisions and evaluate the effectiveness of interventions.
“With our continued commercial success in North America, we are excited to bring NeuroCatch to Australia. This expansion marks a significant milestone in our journey towards a global presence, reflecting our commitment to advancing neurological care and improving brain health.” said Terry Reilly, Chief Commercial Officer of NeuroCatch.
CXDX Connected Diagnostics is the exclusive distributor for Australia. For more information about the NeuroCatch Platform and its availability in Australia, please contact Andrew Sargeant.
Comments